Latest news with #Instruments
Business Recorder
7 days ago
- Business
- Business Recorder
Exporters in PSW system: SBP amends ‘undertaking' for payments via ADs
KARACHI: In light of evolving business dynamics and recent system upgrades, the State Bank of Pakistan (SBP) has amended the undertaking/declaration required from exporters in the Pakistan Single Window (PSW) system for receipt of payments through authorized dealers (ADs). As per instructions contained in Para 5(ii) and 15B(ii) of Chapter 12 (Exports) of Foreign Exchange Manual, whereby exporters of goods are required to file Undertaking/Declaration in PSW system for receipt of payments through an AD, as prescribed by the State Bank of Pakistan. The undertaking/declaration for exports were earlier part of the Manual E-Form/Electronic Form-E (EFE). Now, considering the evolving business dynamics and system upgradations, the SBP has decided to amend the Undertaking/Declaration and accordingly the new format has been issued. PSW designated as FBR's technology partner for WeBOC System The SBP has advised ADs to obtain the revised Undertaking/Declaration from the exporters through the PSW system at the time of initiating their respective export transactions. Further, to mitigate any potential legal risks, ADs may obtain the revised Undertaking/Declaration duly signed by Exporters in manual form as well. ADs are also directed to bring these instructions to the notice of all their constituents and ensure meticulous compliance. The SBP has issued the following revised undertaking/declaration: An incorrect declaration constitutes an offence under Pakistan Penal Code 1860, Foreign ExchangeRegulation Act, 1947 (VII of 1947), Customs Act 1969, and Anti Money Laundering Act 2010. I/We, hereby declare that I/We am/are the sellers/consignors/exporters of the goods described herein in respect of which this declaration is made out and that the particulars given in the Financial Instruments are true and that the invoice value declared in the Financial Instruments in case of firm contracts is full value as contracted with the buyers/in case of consignment sale is a fair value of goods which are being shipped on consignment sale. I/We undertake that I/we shall deliver to the AD the foreign exchange proceeds resulting from the export of these goods, on the due date as per contractual maturity or within such time period as maybe prescribed by State Bank of Pakistan, from the date of shipment/dispatch whichever is earlier. In the event of consignment sale, we undertake to furnish to the AD a fully documented account sale certified by the consignees /Chamber of Commerce of the country of import or any other documents required by the State Bank of Pakistan. I/We declare that nothing material or relevant to the information has been omitted or suppressed and whatever is stated herein is true to my/our knowledge and belief. I/We undertake to submit to the AD within fourteen days of shipment, the documents for negotiation/for sending on collection. I/We hereby expressly authorize the State Bank of Pakistan (SBP) to share my/our outstanding overdue information with ADs/ banks, for the purpose of conducting due diligence related to my/our export activities (Irrespective of the fact whether the same is challenged before a Court or otherwise).I/We also permit the ADs/banks to access my/our outstanding overdue information available on the Exporter's Information Portal (EIP) maintained by SBP. Copyright Business Recorder, 2025
Yahoo
06-06-2025
- Business
- Yahoo
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
Over the past year, advancements in artificial intelligence (AI) and predictive analytics have rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and personalized treatment. AI-powered devices now process large datasets in real time, delivering accurate predictions and actionable insights. Predictive analytics supports early disease detection, risk assessment, maintenance optimization, and cost reduction. According to a January 2025 report, genAI is already generating synthetic medical images, simulating disease progression, and accelerating drug discovery. However, it also introduces new regulatory challenges around safety, transparency, and data integrity. In response, the FDA is implementing a Total Product Lifecycle (TPLC) oversight model with a risk-based approach and enhanced post-market monitoring. Going by data, global AI in the healthcare market is projected to witness a CAGR of 38.5% from 2024 to 2030. However, a deteriorating geopolitical situation, tariffs and supply chain bottlenecks, resulting in a tough situation related to raw material and labor costs, freight charges, as well as healthcare staffing shortages, have put the industry in a tight spot again. Meanwhile, industry players like Penumbra PEN, Integer Holdings ITGR and AngioDynamics ANGO have adapted well to changing consumer preferences and have been witnessing an uptrend in their stock prices. Industry Description The Zacks Medical - Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. This FDA-regulated sector encompasses a vast array of products, from transcatheter valves and orthopedic devices to advanced imaging equipment and robotics. Recent trends highlight the integration of AI in diagnostics, the expansion of telemedicine, the rise of robotic-assisted surgeries, and developments in 3D printing, continuous glucose monitoring systems, gene editing, and nanomedicine. The emergence of generative AI is also reshaping MedTech, prompting the FDA to adopt a TPLC regulatory approach. 3 Trends Shaping the Future of the Medical Instruments Industry Over the past couple of years, there has been a significant increase in the adoption of genAI within the medical instruments space, with 'hyper-personalization' being the primary feature of genAI-driven treatment options. Added to this, genAI is rapidly paving the way for efficient operational management within the industry. GenAI, while analyzing vast and complex genetic and molecular data, is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. A December 2024 report says that global genAI in the healthcare market was valued at $1.8 billion in 2023 and is expected to witness a CAGR of 33.2% from 2024 to 2032. Rapid advancement in deep learning and natural language processing, increasing demand for personalized treatment, growing investment in healthcare AI and rising healthcare data volumes are the major growth factors. This apart, the application of AI in the diagnostics space is growing enormously with the market expected to witness a CAGR of 24.6% by 2034.: The medical instruments space has been benefiting from the ongoing merger and acquisition (M&A) trend. It is a known fact that smaller and mid-sized industry players attempt to compete with the big shots through consolidation. The big players attempt to enter new markets through a niche product. Going by a J.P. Morgan report of 2025, in 2024, MedTech acquisition activity exceeded the previous two years in both deal count and total announced value. A total of 305 M&A transactions were announced, totaling over $63.1 billion for companies in medical devices, diagnostics, therapeutic digital health and commercial research tools, up from 134 deals in 2023. In 2025 so far, notable examples of M&A include Stryker's $4.9 billion acquisition of Inari Medical to expand its peripheral thrombectomy portfolio, Thermo Fisher's $4.1 billion purchase of Solventum's Purification & Filtration business, and Boston Scientific's $664 million acquisition of Bolt Medical to strengthen its position in intravascular lithotripsy solutions.: Per IMF's April 2025 World Economic Outlook, global growth is expected to remain lackluster over the next couple of years. At 2.8% in 2025 and 3.0% in 2026, the forecasts for growth are below the historical (2000–19) average of 3.7%. A few countries, especially low-income developing countries, have seen sizable downside growth revisions, often as a result of increased conflicts and recent tariff shocks. The good news is that global headline inflation is expected to decline to 4.3% in 2025 and to 3.6% in 2026, with advanced economies reaching the targets sooner than emerging market and developing economies. However, the IMF apprehends that the current policy-generated disruptions to the ongoing disinflation process could interrupt the pivot to easing monetary policy, with implications for fiscal sustainability and financial stability. Further, there are chances of higher nominal wage growth, which in some cases reflects the catch-up of real wages, accompanied by weak productivity, which could make it difficult for firms to moderate price increases, especially when profit margins are already squeezed. Zacks Industry Rank Indicates Dull Prospects The Zacks Medical Instruments industry's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates gloomy near-term prospects. The industry, housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #131, which places it in the bottom 46% of 244 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. But it's worth taking a look at the industry's shareholder returns and current valuation first. Industry Underperforms S&P 500, Outperforms Sector The industry has underperformed the Zacks S&P 500 composite but outperformed the sector in the past year. The industry has declined 12.7% compared with the broader sector's decline of 14.7%. The S&P 500 has surged 12.8% in a year. One-Year Price Performance Industry's Current Valuation On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 29.04X compared with the broader industry's 19.18X and the S&P 500's 21.83X. Over the past five years, the industry has traded as high as 40.60X, as low as 25.62X and at the median of 32.52X, as the charts show below. 3 Stocks to Buy Right Now Integer Holdings: Plano, TX-based Integer Holdings is a medical device contract development and manufacturing organization. Its strategic focus on portfolio optimization, including the divestiture of its Non-Medical business, supports its long-term inorganic growth plans. Integer Holdings has established a solid position in the MedTech industry and continues to invest in research and product development, which bodes well for innovation and future revenue growth. The Zacks Consensus Estimate for this Zacks Rank #1 (Strong Buy) company's 2025 sales is pegged at $1.87 billion, indicating a 7.7% rise from 2024. The consensus mark for Integer Holdings' 2025 EPS is pegged at $6.33, indicating an increase of 19.4% from 2024. AngioDynamics: Headquartered in Latham, NY, AngioDynamics' solid prospects with NanoKnife and an increased focus on cancer treatment markets are encouraging. The company boasts a robust product pipeline and strong momentum in geographic expansion. Continued strong sales of Auryon, AlphaVac, and NanoKnife products further strengthen AngioDynamics' outlook. The consensus estimate for this Zacks Rank #1 company's fiscal 2026 sales is pegged at $305 million, indicating a 6.3% rise from fiscal 2025. The consensus mark for AngioDynamics' fiscal 2026 EPS is pegged at a loss of 24 cents, indicating an improvement of 14.9% from the year-ago period figure. Penumbra: Alameda, CA-based Penumbra's consistent revenue growth momentum is being driven by strong patient outcomes with Lightning Flash 2.0, Lightning Bolt 7 and RED 72. The company's vascular and neuro businesses are showing encouraging growth trends. Penumbra's Immersive Healthcare business too is making progress. The Zacks Consensus Estimate for Penumbra's 2025 sales is pegged at $1.35 billion, indicating a 13.4% rise from 2024. The consensus mark for Penumbra's 2025 EPS is pegged at $3.72, indicating an improvement of 67.6% from the year-ago period figure. Penumbra has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Penumbra, Inc. (PEN) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
